Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA-Associated Pancreatic Cancer in the Clinical and Preclinical Setting.
Stossel C, Raitses-Gurevich M, Atias D, Beller T, Glick Gorman Y, Halperin S, Peer E, Denroche RE, Zhang A, Notta F, Wilson JM, O'Kane GM, Haimov Talmoud E, Amison N, Schvimer M, Salpeter SJ, Bar V, Zundelevich A, Tirosh I, Tal R, Dinstag G, Kinar Y, Eliezer Y, Ben-David U, Gavert NS, Straussman R, Gallinger SJ, Berger R, Golan T. Stossel C, et al. Among authors: gavert ns. Cancer Discov. 2023 Aug 4;13(8):1826-1843. doi: 10.1158/2159-8290.CD-22-0412. Cancer Discov. 2023. PMID: 37449843 Free PMC article.
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine.
Geller LT, Barzily-Rokni M, Danino T, Jonas OH, Shental N, Nejman D, Gavert N, Zwang Y, Cooper ZA, Shee K, Thaiss CA, Reuben A, Livny J, Avraham R, Frederick DT, Ligorio M, Chatman K, Johnston SE, Mosher CM, Brandis A, Fuks G, Gurbatri C, Gopalakrishnan V, Kim M, Hurd MW, Katz M, Fleming J, Maitra A, Smith DA, Skalak M, Bu J, Michaud M, Trauger SA, Barshack I, Golan T, Sandbank J, Flaherty KT, Mandinova A, Garrett WS, Thayer SP, Ferrone CR, Huttenhower C, Bhatia SN, Gevers D, Wargo JA, Golub TR, Straussman R. Geller LT, et al. Science. 2017 Sep 15;357(6356):1156-1160. doi: 10.1126/science.aah5043. Science. 2017. PMID: 28912244 Free PMC article.
Ex-vivo organ culture as potential prioritization tool for breast cancer targeted therapy.
Grinshpun A, Gavert N, Granit RZ, Masuri H, Ben-Porath I, Breuer S, Zick A, Rosenberg S, Maoz M, Granit A, Pikarsky E, Straussman R, Peretz T, Sonnenblick A. Grinshpun A, et al. Cancer Biol Ther. 2018 Aug 3;19(8):645-648. doi: 10.1080/15384047.2018.1450114. Epub 2018 Apr 13. Cancer Biol Ther. 2018. PMID: 29565707 Free PMC article.
Ex vivo organotypic cultures for synergistic therapy prioritization identify patient-specific responses to combined MEK and Src inhibition in colorectal cancer.
Gavert N, Zwang Y, Weiser R, Greenberg O, Halperin S, Jacobi O, Mallel G, Sandler O, Berger AJ, Stossel E, Rotin D, Grinshpun A, Kamer I, Bar J, Pines G, Saidian D, Bar I, Golan S, Rosenbaum E, Nadu A, Ben-Ami E, Weitzen R, Nechushtan H, Golan T, Brenner B, Nissan A, Margalit O, Hershkovitz D, Lahat G, Straussman R. Gavert N, et al. Nat Cancer. 2022 Feb;3(2):219-231. doi: 10.1038/s43018-021-00325-2. Epub 2022 Feb 10. Nat Cancer. 2022. PMID: 35145327
40 results